Boris Decourt

Dr. Boris Decourt

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
MAMuna A. Adem
Muna A. Adem
BDBoris Decourt
Boris Decourt
MSMarwan Noel Sabbagh
Marwan Noel Sabbagh
Type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) are chronic, progressive disorders affecting the elderly, which fosters global healthcare concern with the growing aging population. Both T2DM and AD have been linked with increasing age, advanced glycosylation end products, obesity, and insulin resistance. Insulin resistance in the periphery is significant in the development of T2DM and it has been posited that insulin resistance in the brain plays a key role in AD pathogenesis, earning AD the name “type 3 diabetes”. These clinical and epidemiological links between AD and T2DM have become increasingly pronounced throughout the years, and serve as a means to investigate the effects of antidiabetic therapies in AD, such as metformin, intranasal insulin, incretins, DPP4 inhibitors, PPAR-γ agonists, SGLT2 inhibitors. The majority of these drugs have shown benefit in preclinical trials, and have shown some promising results in clinical trials, with the improvement of cognitive faculties in participants with mild cognitive impairment and AD. In this review, we have summarize the benefits, risks, and conflicting data that currently exist for diabetic drugs being repurposed for the treatment of AD.

18 October 2024 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
KNKeith Noorda
Keith Noorda
KNKevin Noorda
Kevin Noorda
MSMarwan N Sabbagh
Marwan N Sabbagh
JBJohn Bertelson
John Bertelson
JSJonathan Singer
Jonathan Singer
BDBoris Decourt
Boris Decourt
Background: Alzheimer’s disease (AD) is the most common neurodegenerative disorder in patient demographics over 65 years old causing debilitating cognitive impairment. Most commonly, AD is diagnosed clinically as “probable AD”, and definitive diagnosis is confirmed through postmortem brain autopsies to detect extracellular amyloid-β (Aβ) plaques and intraneuronal hyperphosphorylated tau tangles. The exact mechanism causing AD is still unknown, but treatments for AD have been actively investigated. Currently, immunotherapies have shown substantial promise in reducing the pathologic and clinical signs of AD. Objective: This review aims to evaluate passive immunotherapies deemed to have promise for further development and use in the treatment of AD. Methods: Immunotherapies were selected via a narrative review of medications that have potential clinical effectiveness with a status of FDA accepted, FDA fast-track, FDA status pending, or emerging therapies poised to pursue FDA approval. Results: This review has yielded two anti-Aβ monoclonal antibodies (mAb) that are currently fully FDA approved, one mAb granted FDA fast-track status, two therapies on hold, three discontinued medications, and three promising emerging therapies. Conclusions: We conclude that, in the near future, passive immunotherapies will be the preferred and evidence-based method of treatment for AD with the presence of brain Aβ deposits for both symptom management and potential slowing of disease progression. Specifically, lecanemab and donanemab will require further clinical studies to optimize patient selection based on safety profiles. Despite some key limitations, these two drugs are paving the way for disease-modifying treatments in patients displaying early signs of amyloid pathology.

2 October 2023 in Expert Opinion on Emerging Drugs
Verified
Journal Article
Closed access
JMJad Majeed
Jad Majeed
MSMarwan N. Sabbagh
Marwan N. Sabbagh
MKMin H. Kang
Min H. Kang
JLJ. Josh Lawrence
J. Josh Lawrence
KPKevin Pruitt
Kevin Pruitt
BDBoris Decourt
Boris Decourt
IntroductionDespite the recent full FDA approval of lecanemab, there is currently no disease modifying therapy (DMT) that can efficiently slow down the progression of Alzheimer's disease (AD) in the general population. This statement emphasizes the need to identify novel DMTs in the shortest time possible to prevent a global epidemic of AD cases as the world population experiences an increase in lifespan.Areas coveredHere, we review several classes of anti-cancer drugs that have been or are being investigated in Phase II/III clinical trials for AD, including immunomodulatory drugs, RXR agonists, sex hormone therapies, tyrosine kinase inhibitors, and monoclonal antibodies.Expert opinionGiven the overall course of brain pathologies during the progression of AD, we express a great enthusiasm for the repositioning of anti-cancer drugs as possible AD DMTs. We anticipate an increasing number of combinatorial therapy strategies to tackle AD symptoms and their underlying pathologies. However, we strongly encourage improvements in clinical trial study designs to better assess target engagement and possible efficacy over sufficient periods of drug exposure.

21 April 2025 in Journal of Clinical and Experimental Neuropsychology
Verified
Journal Article
Closed access
LCLauren Chrzanowski
Lauren Chrzanowski
JSJonathan Singer
Jonathan Singer
PRPeter Rerick
Peter Rerick
LELauren Elliott
Lauren Elliott
DLDanielle E Levitt
Danielle E Levitt
VNVolker Neugebauer
Volker Neugebauer
Inflammation, chronic pain, and hypertension have been identified as risk factors for cognitive decline; few studies have examined the interplay between multiple risk factors and even fewer have considered these factors in underserved rural populations. This study analyzed the relationships between inflammation, chronic pain, and hypertension with cognitive functioning in an underserved, primarily Hispanic, rural population from Project FRONTIER (Facing Rural Obstacles to Healthcare Now Through Intervention, Education, & Research). This epidemiological study enrolled 1,864 participants (Mage = 59.68 years, SDage = 12.21) living in five rural counties in West Texas. Consented participants disclosed medical diagnoses (e.g. chronic pain), completed five cognitive evaluations (i.e. the Repeatable Battery for the Assessment of Neuropsychological Status, the Trails Making Test A and B, and Clock Drawing 1 and 2), and attended a medical examination during which a physician confirmed existing medical conditions (e.g. hypertension) and collected a blood sample for further analysis (e.g. inflammation markers). Analysis via MANOVA revealed a multivariate effect of inflammation (V = .02, F(4, 969) = 3.72, p = .006) and a multivariate effect of hypertension (V = .03, F(4, 969) = 6.69, p < .001). There was no multivariate effect for chronic pain (V = .01, F(4,969) = 2.18, p = .07) and no significant two way or three way interaction. Post-hoc ANOVAs further illustrated the relationships between specific cognitive functioning domains and inflammation or hypertension. The current study findings suggest that underserved rural populations have unique epidemiological experiences that are distinct from prior findings in urban populations. Inflammation and hypertension are important clinical considerations as risk factors for cognitive decline. Future research should explore interventions that support rural-dwelling individuals impacted by provider shortages.

15 July 2025 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
BDBoris Decourt
Boris Decourt
MSMarwan N. Sabbagh
Marwan N. Sabbagh
MMMichelle Mielke
Michelle Mielke

1 September 2025 in Neurology Open Access
Verified
Journal Article
Closed access
CBCherry J. Barragan
Cherry J. Barragan
KBKassu Mehari Beyene
Kassu Mehari Beyene
BDBoris Decourt
Boris Decourt
MSMarwan Noel Sabbagh
Marwan Noel Sabbagh